Patent applications published 10 August 2011
Selected patent applications from the weekly European Patents Bulletin
- Triazole beta carboline derivatives as antidiabetic agents
Merck Sharp & Dohme 2352373*
- Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
Merck Sharp & Dohme; Metabasis Therapeutics 2352374*
- Preparation and use of Pouteria lucuma extract
Rutgers, the State University of New Jersey 2352489*
- Multifunctional self-assembling polymeric nanosystems
Northeastern University 2352490*
- Plant-based granules
Debregeas et Associes Pharma 2352491*
- Small molecule modulators of epigenetic regulation and their therapeutic applications
University of Southern California 2352492*
- Therapeutic, dietary or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compounds containing these compounds
Giuliani 2352493*
- Novel and potent tapentadol dosage forms
Grünenthal 2352494*
- Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
Astellas Ireland 2352495*
- Use of alkanoyl L-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms
Sigma-Tau Industrie-Farmaceutiche Riunite 2352496*
- Compsns containing delta-9-THC-amino acid esters and process of preparation
Elsohly Laboratories 2352497*
- Compsns and methods for minimising or reversing agonist-induced desensitisation
Pharmorx 2352498*
- Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
Janssen Pharmaceutica 2352499*
- Method of inducing negative chemotaxis
Celtaxsys 2352500*
- Compounds for the treatment of osteoporosis and cancers
ChemoCentryx 2352501*
- Limited proteolysis of CD2AP and progression of renal disease
University of Miami; Massachusetts General Hospital 2352502*
- Role of soluble upar in the pathogenesis of proteinuric kidney disease
University of Miami; The General Hospital Corporation d/b/a Massachusetts General Hospital 2352503*
- Treatment of proliferative disorders with a death receptor agonist
National University of Ireland 2352504*
- D-tagatose-based compsns and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof
University of Kentucky Research Foundation 2352505*
- Anti-inflammatory pharmaceutical compsn comprising extracts from Broussonetia papyfera and Lonicera japonica
Pharmaking; KNU-Industry Cooperation Foundation 2352506*
- Peptidomimetic macrocycles with improved properties
Aileron Therapeutics 2352507*
- MUC-1 cytoplasmic domain peptides as inhibitors of cancer
Dana-Farber Cancer Institute; Genus Oncology 2352508*
- HLA-G proteins and pharmaceutical uses thereof
Hla-G Technologies; Commisariat à l’Énergie Atomique et aux Énergies Alternatives 2352509*
- Leptin compsns and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
Tezapsidis, Nikolaos; Greco, Steven; Smith, Mark 2352510*
- Neuropeptide-2-receptor (Y-2R) agonists and uses thereof
F Hoffmann-La Roche 2352511*
- Mechanism of neuromedin U action and uses thereof
Merck Sharp & Dohme 2352512*
- Treating diabetes mellitus using insulin injections with less than daily injection frequency
Novo Nordisk 2352513*
- Methods and kits for treating disease by administering insulin-like growth factor banding protein-2
The Rockefeller University 2352514*
- Method for the treatment of haemophilia
Bayer HealthCare 2352515*
- Immunisation of avians by mucosal administration of non-replicating vectored vaccines
Auburn University 2352516*
- Methods and compsns for treating complement-associated disorders
Alexion Pharmaceuticals 2352517*
- Compsn comprising sortase anchored surface proteins of Streptococcus uberis
The University of Nottingham 2352519*
- Vaccination with poxvirus vectors via mechanical epidermal disruption
The Brigham and Women’s Hospital 2352520*
- Immunoglobulin variants and uses thereof
Genentech; F Hoffmann-La Roche 2352521*
- Bispecific intracellular delivery vehicles
University of Washington; Phaserx 2352522*
- Improved anti-CD19 antibodies
Immunomedics 2352523*
- TCL1 as a transcriptional regulator
The Ohio State University Research Foundation 2352524*
- Somatostatin analogues
Imperial Innovations 2352525*
- Treating cancer stem cells using targeted cargo proteins
Protox Therapeutics 2352526*
- Modulation of toll-like receptor 2 expression by antisense oligonucleotides
Idera Pharmaceuticals 2352527*